Dose and dose-rate distributions produced for multiple treatment beams using (left) intensity-modulated proton therapy and (right) simultaneous dose and dose-rate optimization (SSDRO) for a 10 Gy ...
Please provide your email address to receive an email when new articles are posted on . Until the last decade, efforts to develop a therapy that successfully targeted the KRAS mutation had been futile ...
In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy Many drugs in development continue to follow the historical drug development ...
Plus Therapeutics, Inc. has begun treating patients in its ReSPECT-LM dose optimization trial for REYOBIQ (rhenium Re186 obisbemeda), targeting leptomeningeal metastases (LM), a severe complication of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback